Comparison of the Nancy Index With Continuous Geboes Score: Histological Remission and Response in Ulcerative Colitis.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
30 Jul 2020
Historique:
pubmed: 23 1 2020
medline: 16 6 2021
entrez: 23 1 2020
Statut: ppublish

Résumé

Evidence has been supporting that histological activity of ulcerative colitis [UC] has relevance for the prediction of clinical outcomes in UC patients, such as clinical relapse. In this study, we aimed to compare two histological indexes-the continuous Geboes score [GS] and the Nancy index [NI] -regarding their definitions of histological remission and response, and to determine the ability of faecal calprotectin [FC] levels to discriminate between these histological statuses according to the NI. A large cohort of UC patients [N = 422] who were previously enrolled in other studies was analysed. GS and NI were shown to be strongly correlated [correlation coefficient: 0.882, p <0.001], indicating high accordance in the classification of patients as having/not having histological remission and response. FC levels moderately correlated with NI regarding these histological statuses [correlation coefficient: 0.481, p <0.001], moderately predicted the absence of remission defined by NI >0 {area under the curve (AUC) 0.667 (95% confidence interval [CI] 0.609-0.724)}, and were good predictors of the absence of histological response defined by NI >1 (AUC 0.825 [95% CI 0.777-0.872]). The optimal FC cut-offs determined to predict the NI-defined histological remission and response were 91 μg/g and 106 μg/g, when maximising the negative predictive value [NPV]. Due to the higher applicability of the NI, this study encourages the systematic use of this histological index to assess histological remission and response in UC patients.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Evidence has been supporting that histological activity of ulcerative colitis [UC] has relevance for the prediction of clinical outcomes in UC patients, such as clinical relapse. In this study, we aimed to compare two histological indexes-the continuous Geboes score [GS] and the Nancy index [NI] -regarding their definitions of histological remission and response, and to determine the ability of faecal calprotectin [FC] levels to discriminate between these histological statuses according to the NI.
METHODS METHODS
A large cohort of UC patients [N = 422] who were previously enrolled in other studies was analysed.
RESULTS RESULTS
GS and NI were shown to be strongly correlated [correlation coefficient: 0.882, p <0.001], indicating high accordance in the classification of patients as having/not having histological remission and response. FC levels moderately correlated with NI regarding these histological statuses [correlation coefficient: 0.481, p <0.001], moderately predicted the absence of remission defined by NI >0 {area under the curve (AUC) 0.667 (95% confidence interval [CI] 0.609-0.724)}, and were good predictors of the absence of histological response defined by NI >1 (AUC 0.825 [95% CI 0.777-0.872]). The optimal FC cut-offs determined to predict the NI-defined histological remission and response were 91 μg/g and 106 μg/g, when maximising the negative predictive value [NPV].
CONCLUSIONS CONCLUSIONS
Due to the higher applicability of the NI, this study encourages the systematic use of this histological index to assess histological remission and response in UC patients.

Identifiants

pubmed: 31965158
pii: 5713474
doi: 10.1093/ecco-jcc/jjaa010
doi:

Substances chimiques

Biomarkers 0
Leukocyte L1 Antigen Complex 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1021-1025

Investigateurs

Susana Lopes (S)
Rosa Coelho (R)
José Cotter (J)
Francisca Dias de Castro (FD)
Helena Tavares de Sousa (HT)
Marta Salgado (M)
Patrícia Andrade (P)
Ana Vieira (A)
Pedro Figueiredo (P)
Paulo Caldeira (P)
A Sousa (A)
Maria Duarte (M)
Filipa Ávila (F)
João Silva (J)
Joana Moleiro (J)
Sofia Mendes (S)
Sílvia Giestas (S)
Paula Sousa (P)
Raquel Gonçalves (R)
Bruno Moreira Gonçalves (BM)
Ana Maria Oliveira (AM)
Cristina Chagas (C)

Informations de copyright

Copyright © 2020 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Fernando Magro (F)

Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal.
Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.

Joanne Lopes (J)

Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.

Paula Borralho (P)

Institute of Pathology, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.

Cláudia Camila Dias (CC)

Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
CINTESIS - Centre for Health Technology and Services Research, University of Porto, Porto, Portugal.

Joana Afonso (J)

Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
MedInUP, Centre for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal.

Paula Ministro (P)

Department of Gastroenterology, Centro Hospitalar Tondela-Viseu, Viseu, Portugal.

Mafalda Santiago (M)

CINTESIS - Centre for Health Technology and Services Research, University of Porto, Porto, Portugal.

Karel Geboes (K)

Department of Pathology, University Hospital of KU Leuven and UZ Ghent, Leuven, Belgium.

Fátima Carneiro (F)

Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal.
Institute of Molecular Pathology and Immunology of the University of Porto [Ipatimup], University of Porto, Porto, Portugal.
Institute of Research and Innovation in Health [i3S], University of Porto, Porto, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH